Biotechnological inventions require a deep understanding and expertise in life sciences and in the case law of the European Patent Office and the Federal Patent Court. Especially with biotechnological inventions relating to proteins and DNA, it is often a challenge to meet the requirements of sufficiency of disclosure when drafting patent applications.

We are aware of the importance of biotechnological inventions for our clients and provide them with efficient and cost-effective services. For example, in the case of an invention relating to antibodies, an expensive deposit may be avoided if the claimed antibody can be described by structural features.

In view of the implementation of the European Biotechnology Directive in the European Patent Convention and the German patent law, the industrial application of a sequence or partial sequence of a gene must be disclosed in the patent application. When writing a patent application relating to biotechnology, our attorneys draft a detailed description to comply with this requirement.